GSK sub’s injectable outperforms Gilead in late-stage PrEP trial

Since 2012, when Truvada was first approved as a preventative treatment for HIV, Gilead has had a monopoly on PrEP, or pre-exposure prophylaxis. Now, in a large NIH-backed trial, a new drug from a pair of Big Pharma rivals looked just as effective, if not more.